A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell Lymphomas

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

198 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-09-25

Study Completion Date

2017-01-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to establish the distribution of peripheral T-cell lymphocyte (PTCL) subtypes by re-analysis and re-classification of samples according to the 2008 World Health Organization (WHO) classification of lymphoid neoplasms.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma

NCT01142674

Lymphoma, T-Cell, Peripheral

COMPLETED

Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.

NCT03964480

Peripheral T-Cell Lymphoma

RECRUITING

Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma

NCT05182957

Relapsed/Refractory Peripheral T-cell Lymphoma

UNKNOWN PHASE2

Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST)

NCT05934864

Peripheral T Cell Lymphoma

RECRUITING

Study of Prognostic Factors in Adult Lymphoblastic Lymphoma

NCT03571997

Lymphoblastic Lymphoma

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a retrospective, non-interventional and, post-authorization observational study of other designs (PAS-OD).

This multicenter trial will be conducted in Spain. Retrospective review of medical records and initial tumor biopsies of participants diagnosed with PTCL in the period of 6 years between 01/01/2008 and 31/12/2013 will be performed. Initial tumor biopsies and histological preparations, filed and previously anonymized, will be sent to the central laboratory for assessment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymphoma, T-Cell, Peripheral

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

Assessment of tumor biopsies and histological preparations of participants diagnosed with peripheral T-cell lymphoma (PTCL) in the six years between 01 January 2008 and 31 December 2013 will be performed.

No Intervention

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No Intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants diagnosed with PTCL in the six years between 01/01/2008 and 31/12/2013.
* Availability of initial tumor biopsy diagnosis in paraffin block (node or core biopsy of 16-18mm).
* PTCL subtypes permitted by WHO 2008 classification of lymphoid neoplasms:

* Natural killer/ T-lymphocytes (NK /T-cell) lymphoma extranodal nasal type
* Enteropathic T-cell lymphoma
* Hepatosplenic T-cell lymphoma
* Peripheral T-cell lymphoma, not otherwise specified
* Angioimmunoblastic T-cell lymphoma
* Anaplastic large cell lymphoma, Anaplastic lymphoma kinase positive (ALK)+
* Anaplastic large cell lymphoma, ALK-